

*E 2*

10. (Amended) A composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and a polynucleotide or salt thereof according to any one of Claims 1, 2 or 6, or a double stranded polynucleotide or salt thereof according to Claim 8 or 9 as an essential ingredient.

Please add the following new claims:

*B 3*

30. (Added) The double stranded chain-shortened polynucleotide or salt thereof according to claim 17, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

31. (Added) A polynucleotide or salt thereof according to Claims 7, which is in form of a double stranded polynucleotide or salt thereof formed from two polynucleotides or salts thereof which are capable of forming a double strand.

32. (Added) A composition comprising of a complex formed from a carrier effective for introducing a medicament into a cell and a polynucleotide or salt thereof according to Claims 7 or a double stranded polynucleotide or salt thereof according to Claim 8 or 9 as an essential ingredient.

Please cancel claims 3, 16, 18, 19, 20, 25 and 26 without prejudice.

A marked-up version of the amended claims is included in the attachment hereto.

**Remarks**

Claims 3, 6 and 7 have been objected to because of formal problems. These problems have been remedied in the current amendment. Claim 30 has replaced claim 3 and the Examiner's suggested language has been employed in claims 6 and 7.